These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 12432865)
1. Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Sokolov OY; Meshavkin VK; Kost NV; Zozulya AA Bull Exp Biol Med; 2002 Feb; 133(2):133-5. PubMed ID: 12432865 [TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Zozulya AA; Kost NV; Yu Sokolov O; Gabaeva MV; Grivennikov IA; Andreeva LN; Zolotarev YA; Ivanov SV; Andryushchenko AV; Myasoedov NF; Smulevich AB Bull Exp Biol Med; 2001 Apr; 131(4):315-7. PubMed ID: 11550013 [TBL] [Abstract][Full Text] [Related]
3. [The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic selank]. Kozlovskiĭ II; Andreeva LA; Kozlovskaia MM; Nadorova AV; Kolik LG Eksp Klin Farmakol; 2012; 75(2):10-3. PubMed ID: 22550852 [TBL] [Abstract][Full Text] [Related]
4. [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. Zolotarev IuA; Sokolov OIu; Kost NV; Vas'kovskiĭ BV; Miasoedov NF; Zozulia AA Bioorg Khim; 2004; 30(3):234-40. PubMed ID: 15344652 [TBL] [Abstract][Full Text] [Related]
5. [Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study]. Narkevich VB; Kudrin VS; Klodt PM; Pokrovskiĭ AA; Kozlovskaia MM; Maĭskiĭ AI; Raevskiĭ KS Eksp Klin Farmakol; 2008; 71(5):8-12. PubMed ID: 19093364 [TBL] [Abstract][Full Text] [Related]
6. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Kasian A; Kolomin T; Andreeva L; Bondarenko E; Myasoedov N; Slominsky P; Shadrina M Behav Neurol; 2017; 2017():5091027. PubMed ID: 28280289 [TBL] [Abstract][Full Text] [Related]
7. Naloxone-blocked depriming effect of anxiolytic selank on apomorphine-induced behavioral manifestations of hyperfunction of dopamine system. Meshavkin VK; Kost NV; Sokolov OY; Zolotarev YA; Myasoedov NF; Zozulya AA Bull Exp Biol Med; 2006 Nov; 142(5):598-600. PubMed ID: 17415472 [TBL] [Abstract][Full Text] [Related]
8. Spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, potentiates leu-enkephalin-induced anti-allodynic and antinociceptive effects in mice. Honda M; Okutsu H; Matsuura T; Miyagi T; Yamamoto Y; Hazato T; Ono H Jpn J Pharmacol; 2001 Dec; 87(4):261-7. PubMed ID: 11829145 [TBL] [Abstract][Full Text] [Related]
9. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Kost NV; Sokolov OIu; Gabaeva MV; Grivennikov IA; Andreeva LA; Miasoedov NF; Zozulia AA Bioorg Khim; 2001; 27(3):180-3. PubMed ID: 11443939 [TBL] [Abstract][Full Text] [Related]
10. [COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]. Vasil'eva EV; Kondrakhin EA; Salimov RM; Kovalev GI Eksp Klin Farmakol; 2016; 79(9):3-11. PubMed ID: 29787664 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of enkephalin degrading enzymes by metal chelating reagents. Altstein M; Blumberg S; Vogel Z Adv Biochem Psychopharmacol; 1982; 33():261-70. PubMed ID: 6751033 [TBL] [Abstract][Full Text] [Related]
12. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Kozlovskaya MM; Kozlovskii II; Val'dman EA; Seredenin SB Neurosci Behav Physiol; 2003 Nov; 33(9):853-60. PubMed ID: 14969422 [TBL] [Abstract][Full Text] [Related]
13. [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Kost NV; Sokolov OIu; Gabaeva MV; Zolotarev IuA; Malinin VV; Khavinson VKh Izv Akad Nauk Ser Biol; 2003; (4):427-9. PubMed ID: 12942748 [TBL] [Abstract][Full Text] [Related]
14. Differential effects on active avoidance performance and locomotor activity of two major enkephalin metabolites, tyr-gly-gly and des-tyr-[leu]enkephalin. Weinberger SB; Martinez JL Life Sci; 1988; 43(9):769-76. PubMed ID: 3412113 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic study of anxiolytic effects of new cholecystokinin receptor antagonists in animals with different levels of emotionality. Kolik LG; Gudasheva TA; Seredenin SB Bull Exp Biol Med; 2003 May; 135(5):440-4. PubMed ID: 12910281 [TBL] [Abstract][Full Text] [Related]
16. [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]. Sarkisova KIu; Kozlovskiĭ II; Kozlovskaia MM Zh Vyssh Nerv Deiat Im I P Pavlova; 2008; 58(2):226-37. PubMed ID: 18661785 [TBL] [Abstract][Full Text] [Related]
17. Isolation and identification of an endogenous inhibitor of enkephalin-degrading enzymes from bovine spinal cord. Nishimura K; Hazato T Biochem Biophys Res Commun; 1993 Jul; 194(2):713-9. PubMed ID: 8343155 [TBL] [Abstract][Full Text] [Related]
18. Only tyrosine-containing metabolites of [Leu]enkephalin impair active avoidance conditioning in mice. Janak PH; Martinez JL Pharmacol Biochem Behav; 1990 Dec; 37(4):655-9. PubMed ID: 2093169 [TBL] [Abstract][Full Text] [Related]
19. [The pharmacogenetic concept of the anxio-selective effect]. Seredenin SB; Voronina TA; Neznamov GG; Blednov IuA; Badyshtov BA; Viglinskaia IV; Kozlovskaia MM; Kolotilinskaia NV; Iarkova MA; Savel'ev VL; Garibova TL; Val'dman EA Vestn Ross Akad Med Nauk; 1998; (11):3-9. PubMed ID: 9889697 [TBL] [Abstract][Full Text] [Related]
20. [Selank and short peptides of Taftsin derivatives in regulation of adaptive behavior of animals in stress]. Kozlovskaia MM; Kozlovskiĭ II; Val'dman EA; Seredenin SB Ross Fiziol Zh Im I M Sechenova; 2002 Jun; 88(6):751-61. PubMed ID: 12154572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]